Pacific Biosciences of California Inc., popularly known as PacBio, develops, manufactures and markets sequencing systems, which help in studying synthesis, composition, structure and regulation of deoxyribonucleic acid, popularly known as DNA. PacBio's products are based on Single Molecule, Real-Time (SMRT) technology. SMRT generates long reads that help in assembling a whole human genome from scratch, without using an existing reference genome as a template. This process is known as de novo assembly. To observe DNA replication process smoothly, PacBio offers the SMRT Cell, Phospholinked nucleotides and The PacBio RS II System. The PacBio RS II System includes the PacBio RS II instrument, consumables and software. PacBio launched its new Sequel system based on SMRT technology. PacBio deferred the gain from the Reverse Termination Fee from Illumina until the date when the associated contingency was resolved.
Info & Links
CEO
Christian O. Henry
Headquarters
1305 O'BRIEN DRIVE MENLO PARK, CA 94025, UNITED STATES
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.